- In a presentation today at the European Society of Cardiology Congress in London, pooled data from the ODYSSEY clinical trial program show Praluent (alirocumab) significantly lowered bad cholesterol (LDL-C). The analysis included 1,257 patients with heterozygous familial hypercholesterolemia (HeFH), a genetic predisposition for high cholesterol.
- At week 24, patients receiving Praluent experienced an average 56% greater reduction in LDL-C versus placebo (p<0.0001). Reductions were observed as early as week 4 and were maintained until week 78, the duration of therapy.
- Only ~20% of HeFH patients are able to reduce their LDL-C level below 100 mg/dL with statins. In this analysis, 75% of HeFH patients who added Praluent to their standard-of-care treatment (which included statins) were able to lower their LDL-C below 100 mg/dL.
- Praluent, approved by the FDA in July, was co-developed by Regeneron Pharmaceuticals (NASDAQ:REGN -2%) and Sanofi (SNY -1.9%).